1. Home
  2. BMBL vs FULC Comparison

BMBL vs FULC Comparison

Compare BMBL & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bumble Inc.

BMBL

Bumble Inc.

HOLD

Current Price

$2.84

Market Cap

405.6M

Sector

Technology

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.69

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMBL
FULC
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
405.6M
467.8M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
BMBL
FULC
Price
$2.84
$3.69
Analyst Decision
Hold
Buy
Analyst Count
13
8
Target Price
$4.46
$16.38
AVG Volume (30 Days)
2.9M
2.4M
Earning Date
05-05-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.34
N/A
Revenue
$965,658,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.61
$2.83
52 Week High
$8.63
$15.74

Technical Indicators

Market Signals
Indicator
BMBL
FULC
Relative Strength Index (RSI) 33.44 25.82
Support Level $2.68 N/A
Resistance Level $3.85 $8.18
Average True Range (ATR) 0.17 0.35
MACD -0.02 -0.34
Stochastic Oscillator 5.50 18.40

Price Performance

Historical Comparison
BMBL
FULC

About BMBL Bumble Inc.

Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: